Unknown

Dataset Information

0

High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.


ABSTRACT: BACKGROUND AND OBJECTIVES:Different rituximab protocols are used to treat membranous nephropathy. We compared two rituximab protocols in patients with membranous nephropathy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at 2-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m2 at 1-week interval. We measured serum rituximab levels and compared remission at month 6 and before any treatment modification and analyzed factors associated with remission and relapses. RESULTS:Remissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX cohort (P=0.02) at month 6, respectively, and in 24 (86%) versus 18 (67%) participants (P=0.12) before treatment modification, respectively. Median time to remission was 3 [interquartile range (IQR), 3-9] and 9 [IQR, 6-12] months for NICE and GEMRITUX cohorts respectively (P=0.01). Participants from the NICE cohort had higher circulating level of rituximab and lower CD19 counts (3.3 µg/L [IQR, 0.0-10.8] versus 0.0 [IQR, 0.0-0.0] P<0.001 and 0.0 [IQR, 0.0-2.0] versus 16.5 [IQR, 2.5-31.0] P<0.001) at month 3, lower level of anti-PLA2R1 antibodies at month 6 (0.0 [IQR, 0.0-8.0] versus 8.3 [IQR, 0.0-73.5] P=0.03). In the combined study population, lower epitope spreading at diagnosis and higher rituximab levels at month 3 were associated with remissions at month 6 (13/26 (50%) versus 22/29 (76%) P=0.05 and 2.2 µg/ml [IQR, 0.0-10.9] versus 0.0 µg/ml [IQR, 0.0-0.0] P<0.001 respectively). All non-spreaders entered into remission whatever the protocol. Eight of the 41 participants who reached remission had relapses. Epitope spreading at diagnosis (8/8 (100%) versus 16/33 (48%) P=0.01) and incomplete depletion of anti-PLA2R1 antibodies at month 6 (4/8 (50%) versus 5/33 (9%) P=0.05) were associated with relapses. CONCLUSIONS:Our work suggests that higher dose rituximab protocol is more effective on depletion of B-cells and lack of epitope spreading is associated with remission of membranous nephropathy.

SUBMITTER: Seitz-Polski B 

PROVIDER: S-EPMC6682825 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

Seitz-Polski Barbara B   Dahan Karine K   Debiec Hanna H   Rousseau Alexandra A   Andreani Marine M   Zaghrini Christelle C   Ticchioni Michel M   Rosenthal Alessandra A   Benzaken Sylvia S   Bernard Ghislaine G   Lambeau Gérard G   Ronco Pierre P   Esnault Vincent L M VLM  

Clinical journal of the American Society of Nephrology : CJASN 20190724 8


<h4>Background and objectives</h4>Different rituximab protocols are used to treat membranous nephropathy. We compared two rituximab protocols in patients with membranous nephropathy.<h4>Design, setting, participants, & measurements</h4>Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at 2-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX)  ...[more]

Similar Datasets

| S-EPMC8071636 | biostudies-literature
| S-EPMC10831377 | biostudies-literature
| S-EPMC10517553 | biostudies-literature
| S-EPMC8071613 | biostudies-literature
| S-EPMC8207302 | biostudies-literature
| S-EPMC3609136 | biostudies-literature
| S-EPMC3913240 | biostudies-literature
| S-EPMC6691064 | biostudies-literature
| S-EPMC10403650 | biostudies-literature
| S-EPMC5328151 | biostudies-literature